Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance

Kerry L. LaPlante\textsuperscript{a}, Abhay Dhand\textsuperscript{b}, Kelly Wright\textsuperscript{c} and Melanie Lauteri\textsuperscript{c}

\textsuperscript{a}College of Pharmacy, University of Rhode Island, Kingston, RI, USA; \textsuperscript{b}Westchester Medical Center, New York Medical College, Valhalla, NY, USA; \textsuperscript{c}Paratek Pharmaceuticals, Inc, King of Prussia, PA, USA

**ABSTRACT**

The progressive increase in antibiotic resistance in recent decades calls for urgent development of new antibiotics and antibiotic stewardship programs to help select appropriate treatments with the goal of minimising further emergence of resistance and to optimise clinical outcomes. Three new tetracycline-class antibiotics, eravacycline, omadacycline, and tigecycline, have been approved within the past 15 years, and represent a new era in the use of tetracyclines. These drugs overcome the two main mechanisms of acquired tetracycline-class resistance and exhibit a broad spectrum of \textit{in vitro} activity against gram-positive, gram-negative, anaerobic, and atypical pathogens, including many drug-resistant strains. We provide an overview of the three generations of tetracycline-class drugs, focussing on the efficacy, safety, and clinical utility of these three new third-generation tetracycline-class drugs. We also consider various scenarios of unmet clinical needs where patients might benefit from re-engagement with tetracycline-class antibiotics including outpatient treatment options, patients with known \textit{b}-lactam antibiotic allergy, reducing the risk of \textit{Clostridioides difficile} infection, and their potential as monotherapy in polymicrobial infections while minimising the risk of any potential drug-drug interaction.

**KEY MESSAGES**

- The long-standing safety profile and broad spectrum of activity of tetracycline-class antibiotics made them a popular choice for treatment of various bacterial infections; unfortunately, antimicrobial resistance has limited the utility of the early-generation tetracycline agents.
- The latest generation of tetracycline-class antibiotics, including eravacycline, tigecycline, and omadacycline, overcomes the most common acquired tetracycline resistance mechanisms.
- Based on \textit{in vitro} characteristics and clinical data, these newer tetracycline agents provide an effective antibiotic option in the treatment of approved indications in patients with unmet clinical needs – including patients with severe penicillin allergy, with renal or hepatic insufficiency, recent \textit{Clostridioides difficile} infection, or polymicrobial infections, and those at risk of drug–drug interactions.

**Introduction**

Over the past decade, there has been a substantial increase in the number of infections caused by bacteria that are resistant to one or more antibiotics [1]. Annually, more than 2.8 million antibiotic-resistant infections occur in the United States with approximately 35,000 deaths attributed to antibiotic-resistant infections [1]. This increased morbidity and mortality caused by antibiotic-resistant infections is associated with a considerable economic burden: $4.6 billion is spent annually to treat infections caused by six multi-drug-resistant bacteria alone [2]. The US Centres for Disease Control and Prevention (CDC) has identified major bacterial and fungal drug-resistance threats, of which carbapenem-resistant \textit{Acinetobacter} and Enterobacteriales, drug-resistant \textit{Neisseria gonorrhoeae}, and \textit{Clostridioides difficile} pose urgent threats [1]. Recognising the need for creative approaches to address the problem of a dwindling antimicrobial research and development pipeline, in 2010 the Infectious Diseases Society of America launched the 10 \times \text{’}20 initiative to encourage the development of 10 new systemic antibacterial agents by 2020 [3]. In total, 14 new agents were approved between 2010 and 2020, with several others in late-stage clinical development [4]. Of these newly approved agents,
two were novel third-generation tetracycline-class antibiotics (eravacycline and omadacycline), with a third (tigecycline) approved by the US Food and Drug Administration (FDA) in 2005. This commentary focuses on the history of the three generations of tetracycline-class antibiotics, their mechanism of action, the emergence of resistance, and relevant data regarding the clinical utility of newer tetracycline agents.

**History and clinical utility of tetracycline-class drugs**

The first tetracycline-class drugs were discovered in the late 1940s, isolated from *Streptomyces* spp [5]. Aureomycin (also known as chlorotetracycline) was approved for use in the United States in 1948; the other three commonly used first- and second-generation tetracycline-class drugs (tetracycline, doxycycline, and minocycline) were approved in 1954, 1967, and 1971, respectively. No new tetracycline-class drugs were then developed until the third generation in the 2000s [5].

Tetracycline-class drugs inhibit bacterial protein synthesis by binding to bacterial ribosomes and interacting with the highly conserved 16S ribosomal RNA (rRNA) in the 30S ribosomal subunit [6]. The drug class demonstrates a broad spectrum of activity against a wide range of gram-positive, gram-negative, and atypical pathogens, resulting in the extensive use of the tetracycline class in both humans and animals after the drugs were initially discovered [5]. Indications for treatment of bacterial infections include pneumonia; skin infections; bone and joint infections; sexually transmitted infections including chlamydia, syphilis, and gonorrhea; intra-abdominal infections; biothreat pathogens, including *Yersinia pestis*, *Bacillus anthracis*, and *Francisella tularensis*; and other specific bacterial pathogens such as *Rickettsia* spp, *Borrelia* spp, and nontuberculous mycobacteria. Tetracycline-class agents are recommended as first-line treatment options for many of these indications [7–13].

**Tetracycline resistance**

While tetracycline-class drugs have a broad spectrum of antibacterial activity and many clinical applications, their utility has declined over time through the emergence of antibiotic resistance. In the early antibiotic era (up until the mid-1950s), most commensal and pathogenic bacteria remained susceptible to tetracyclines; however, within 2 years of the approval of aureomycin, resistance had emerged in *Staphylococcus aureus* [14]. In 1954, resistant strains of *Streptococcus pyogenes* were first noted in patients with burn injuries [15]. The first-generation tetracycline and second-generation minocycline and doxycycline demonstrated improved activity versus aureomycin against *S. aureus*, yet many *Streptococcus* species remained resistant. By 1968, approximately 23% of *Streptococcus pneumoniae* isolates were resistant to all three drugs, and at least half of these resistant infections were acquired outside of hospital settings [16]. The increasing rates of acquired resistance to tetracycline-class drugs during the 1960s and 1970s, and the growing availability of other antibiotic agents such as cephalosporins and fluoroquinolones [17], led to this class being used mainly as a second-line treatment option.

Multiple mechanisms confer acquired resistance to the tetracycline class, the most common being efflux pumps and ribosomal protection proteins (Figure 1). Efflux pumps are antiporters that exchange a monocationic magnesium–tetracycline complex for a proton, thus actively pumping antibiotics out of the bacterial cell. Efflux pumps are found in both gram-positive, e.g. Tet(K) and Tet(L), and gram-negative bacteria, e.g. Tet(A) and Tet(B), including *Staphylococcus*, *Streptococcus*, *Klebsiella*, and *Escherichia* species [5,18,19]. Ribosomal protection proteins such as Tet(O) and Tet(M), found in both gram-positive and gram-negative organisms, are cytoplasmic proteins that protect ribosomes from the inhibitory action of tetracycline-class drugs [19]. Although the exact mechanism of resistance is unclear, it is likely that the proteins cause a conformational change in the structure of the ribosome, either preventing tetracycline binding or resulting in dissociation [18]. Two other acquired tetracycline resistance mechanisms that are less common include target modification, where a mutation in the ribosomal RNA of the target binding site reduces antibiotic binding affinity; and drug degradation, where enzymatic action mediated by tet(X) genes degrades antibiotic products [5,18]. However, tet(X) could be an emerging threat to susceptibility to all tetracyclines particularly gram-negative pathogens [20]. In addition to these acquired resistance mechanisms, intrinsic resistance to tetracycline-class drugs has been noted in *Providencia* spp, *Proteus mirabilis*, and *Pseudomonas aeruginosa* among gram-negative organisms [21–23].

Since the 1990s, the prevalence of *S. aureus*, *S. pneumoniae*, and *S. pyogenes* resistance to β-lactams and non-β-lactams, such as macrolides and tetracycline-class antibiotics, has steadily increased. The
SENTRY Antimicrobial Surveillance Program reported that the global occurrence of methicillin-resistant *S. aureus* (MRSA) increased from 33% in 1997–2000 to 44% in 2005–2008, with the highest rates in North America [24]. A recent analysis of data from 329 US hospitals also showed that *S. pneumoniae* macrolide resistance was >25% in most regions and nearly 40% overall isolates tested [25]. In general, similar rates of resistance are seen in *Streptococcus* spp to the first-generation tetracycline and second-generation doxycycline, whereas *S. aureus* resistance rates decrease with later-generation tetracyclines [26–28]. As rates of antimicrobial resistance continue to increase, new antibiotics, including third-generation tetracycline-class drugs, offer an important therapeutic option for various bacterial infections.

**Generations of tetracycline-class drugs: similarities and differences**

All tetracycline-class drugs share a core chemical structure, with variations in the side groups (Figure 2). The generations of tetracycline-class drugs are defined by the methodology used to develop the drug: the first generation is obtained from biosynthesis, the second generation is semi-synthetic products, and the third generation is entirely synthetic and can therefore have more elaborate side chains than earlier generations; this enhances their antibacterial activity (Figure 2). In all tetracycline-class drugs, the amino group present in the C4 position of the A ring is vital for antibiotic activity [29]. While the second-generation drugs have increased oral bioavailability compared with the first generation, they largely did not overcome the acquired resistance mechanisms through efflux pumps and ribosomal protection proteins, with the exception of *S. aureus* efflux pumps for minocycline [30]. Additionally, inducible resistance against doxycycline has been observed in previously susceptible community-associated MRSA isolates [31]. In the third-generation tetracycline-class drugs, the addition of a lipophilic side group at the C9 position on the D ring enhances the antibiotic activity further, and all three are designed to overcome the two main tetracycline resistance mechanisms [27]. While only tetracycline is still in routine use from the first generation of tetracycline-class drugs (developed between 1948 and 1963), two second-generation drugs (developed between 1965 and 1972), doxycycline and minocycline, are also still...
routinely used in humans. Tetracycline is currently only available in an oral formulation, whereas second-generation drugs are available in both oral and intravenous (IV) formulations. Of the third-generation drugs, eravacycline and tigecycline are available only in IV formulation, whereas omadacycline is available in both oral and IV formulations.

**In vitro activity of tetracycline-class antibiotics**

Tetracycline-class drugs show a broad range of *in vitro* activity against gram-positive, gram-negative, anaerobic and atypical pathogens [5]. While the clinical relevance of *in vitro* activity is unknown, third-generation tetracycline-class drugs have improved activity against many common community-acquired bacterial pneumonia (CABP) and skin and skin structure infection pathogens when compared with first-generation tetracycline (Table 1) [32].

Minimum inhibitory concentrations (MICs) obtained from *in vitro* studies provide the key context for antibiotic selection against those pathogens. Lower MICs indicate that less drug is required for inhibition of organism growth, thus providing greater antimicrobial activity than a drug with a higher MIC value, assuming pharmacodynamic (PD) exposure is the same [33]. Susceptibility testing varies and is based on breakpoint criteria developed by two organisations, the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [27,28]. In general, CLSI breakpoints have been approximately fourfold higher than EUCAST, but CLSI breakpoints for *S. pneumoniae* were revised in 2013 to more accurately reflect the presence or absence of *tet* resistance genes [27]. There remains an unmet need for harmonisation of tetracycline breakpoints against other pathogens, as variations between the two criteria show large ranges in susceptibility rates against other pathogens, such as MRSA (Table 2).

For the tetracycline-class agents, MICs for a particular pathogen are generally substantially lower for the
third-generation drugs relative to values for tetracycline and doxycycline [34]. Third-generation tetracycline-class drugs also maintain their activity against pathogens that are resistant to first- and second-generation drugs, and overall, show more potent antibacterial activity than older generations (Table 3) [32,34–37]. A full list of susceptible pathogens is provided in Table 4.

### Table 1. In vitro activity of tetracycline and third-generation tetracycline-class drugs against select gram-positive, gram-negative, and anaerobic pathogens [35,103,104].

| Organism (n) | Tetracycline | Omadacyclinea | Eravacyclineb |
|--------------|--------------|--------------|--------------|
| *Bacteroides fragilis* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
| Methicillin resistant | – | – | 0.12 | 99.7 | – | – |
| Methicillin sensitive | 0.25 | 97.8 | 0.25 | 97.8 | 0.12 | 99.7 |

| *Enterococcus faecalis* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Tetracycline resistant  | 0.25 | 97.8 | 0.25 | 97.8 | 0.12 | 99.7 |

| *Escherichia coli* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------|--------------|---------|--------------|---------|--------------|---------|
| ESBL phenotype | >8 | 88.1 | 0.25 | 100 | 2 | – |

| *Haemophilus influenzae* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| 1 | 99.7 | 0.25 | 90.5 | 1 | 99.7 | 0.25 |

| *Klebsiella pneumoniae* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| ESBL phenotype | >16 | 98.3 | 0.25 | 100 | 2 | – |

| *Staphylococcus aureus* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Methicillin resistant | 0.12 | 99.7 | 0.25 | 95.2 | 0.5 | 97.2 |

| *Streptococcus pyogenes* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Methicillin resistant | 0.12 | 99.7 | 0.25 | 95.2 | 0.12 | 80.8 |

| *Streptococcus pneumoniae* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|---------------------------|--------------|---------|--------------|---------|--------------|---------|
| Penicillin resistant, oral | >4 | 79.7 | 0.12 | 86.9 | 0.12 | 97.6 |

| *Streptococcus pyogenes* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| TetR | – | – | 64 | 2 |

| *Enterococcus faecalis* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Minocycline NR | – | – | 78.0 | 20.7 | 78.0 | 22.0 |

| *Doxycycline* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|---------------|--------------|---------|--------------|---------|--------------|---------|
| Minocycline NR | – | – | 71.7 | 27.3 | 72.7 | 26.4 |

| *Streptococcus pneumoniae* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|---------------------------|--------------|---------|--------------|---------|--------------|---------|
| Penicillin resistant, oral | >4 | 48.5 | 0.12 | 84.9 | 0.12 | 95.1 |

| *Streptococcus pyogenes* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Penicillin resistant, oral | >4 | 61.0 | 0.12 | 84.9 | 0.12 | 95.1 |

| *Streptococcus pyogenes* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* |
|-------------------------|--------------|---------|--------------|---------|--------------|---------|
| Penicillin resistant, oral | >4 | 0 | 0.12 | 82.4 | 0.12 | 91.2 |

### Table 2. Susceptibility rates for first- and second-generation tetracycline-class drugs against common gram-positive pathogens [27,28].

| Organism | Antibiotica | MIC (µg/mL) | % Susceptible / % Resistant |
|----------|-------------|-------------|----------------------------|
| *Streptococcus pneumoniae* | Tetracycline | <0.06 | 93.6 / 6.4 |
| | Doxycycline | <0.06 | 97.1 / 2.9 |

| *Streptococcus pyogenes* | Tetracycline | <0.06 | 94.4 / 5.6 |
| | Doxycycline | <0.06 | 97.1 / 2.9 |

### Table 3. In vitro activity of tetracycline-class drugs in the presence and absence of acquired tetracycline resistance genes [34,98,102,103].

| Strain | Tetb determinant | Mechanism type | MIC range (µg/mL) |
|--------|-----------------|----------------|-------------------|
| *Staphylococcus aureus* | None | – | ≤0.06–0.25 |
| | tet(M) | RPPs | 32 to >64 |
| | tet(K) | Efflux pump | 16–32 |

| *Streptococcus pneumoniae* | None | – | ≤0.06–0.25 |
| | tet(M) | RPPs | 4–64 |
| | tet(K) | Efflux pump | 1–4 |

| *β-hemolytic streptococci* | None | – | ≤0.06–0.125 |
| | tet(M) | RPPs | 4–64 |

MIC: minimum inhibitory concentration; NR: not recorded; RPP: ribosomal protection protein.

*aSusceptibility data are derived from FDA identified breakpoints. Criteria as published by CLSI.

*bBreakpoints unavailable.

CLSI: Clinical and Laboratory Standards Institute; ESBL: extended-spectrum β-lactamase; FDA: Food and Drug Administration; MIC: minimum inhibitory concentration.

**Tetracycline is considered a first-generation tetracycline-class drug. Doxycycline and minocycline are second-generation tetracycline-class drugs.

*bUsing CLSI 2013 susceptibility breakpoint for doxycycline of ≤0.25 µg/mL applied to the minocycline.

**T. pyogenes and S. agalactiae.
**Table 4.** Indications and susceptible pathogens for third-generation tetracycline-class drugs [9,10,12].

| Antibiotic | Indication | Susceptible microorganisms |
|------------|------------|---------------------------|
| Tigecycline | Complicated skin and skin structure infection | Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloaceae, Klebsiella pneumoniae, and Bacteroides fragilis |
| Community-acquired bacterial pneumonia | Complicated intra-abdominal infection | Citrobacter freundii, E. cloacae, E. coli, Klebsiella oxytoca, K. pneumoniae, E. faecalis (vancomycin-susceptible isolates), S. aureus (methicillin-susceptible and -resistant isolates), S. anginosus group, B. fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros |
| Eravacycline | Complicated intra-abdominal infection | E. coli, K. pneumoniae, C. freundii, E. cloacae, K. oxytoca, E. faecalis, Enterococcus faecium, S. aureus, S. anginosus group, C. perfringens, Bacteroides spp, and Parabacteroides distasonis |
| Omadacycline | Acute bacterial skin and skin structure infection (ABSSSI) | S. aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, S. pyogenes, S. anginosus group, E. faecalis, E. cloacae, and K. pneumoniae |
| Community-acquired bacterial pneumonia | S. pneumoniae, S. aureus (methicillin-susceptible isolates), H. influenzae, Haemophilus parainfluenzae, K. pneumoniae, L. pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae |

**Table 5.** Pharmacokinetic parameters of tetracycline-class drugs [8–13,47].

| Antibiotic | Maintenance dose | Dosing frequency | Food effect ($C_{\text{max}}$ decrease) | Protein binding | Half-life | Metabolism | Excretion |
|------------|------------------|------------------|----------------------------------------|-----------------|----------|------------|-----------|
| Tetracycline | Oral: 250/500 mg | Oral: BID to QID | 50% | 55–64% | 6–11 h | Yes | Fecal: 20–60% |
| | Doxycycline | Oral: 100 mg | 20% | 12–25 h | Yes | Renal: 30% |
| | Minocycline | Oral: 100 mg | Oral: BID | – | 76% | 11–24 h | Yes | Fecal: 20–35% |
| | Oral: 50/75/100 mg | | | | | | Renal: 5–12% |
| | Omadacycline | Oral: 300 mg | Oral: QD | 40–59% | 20% | 16 h | Yes | Fecal (oral): 81% |
| | Tigecycline | Oral: 50 mg | Oral: BID | NA | 71–89% | 42 h | None | Biliary/Fecal: 59% |
| | Eravacycline | Oral: 1 mg/kg | IV: BID | NA | 79–90% | 20 h | CYP3A4- and FMO-mediated oxidation | Biliary/Fecal: 47% |

BID: twice daily; IV: intravenous; NA: not applicable; QD: daily; QID: four times daily.

Third-generation tetracycline-class agents evade the two most common mechanisms of tetracycline resistance, but the emergence of resistance to these newer drugs remains a concern. Current resistance mechanisms to tigecycline mostly involve overexpression of efflux pumps and enzymatic inactivation, including by tet(X), a gene encoding a flavin-dependent monoxygenase [38–40]. Resistance to all tetracycline-class antibiotics has now been noted in carbapenem- and colistin-resistant multidrug-resistant pathogens that carry the tet(X) gene or homologs [41,42]. A global survey of the in vitro activity of tigecycline and comparators assessing trends in susceptibility from 2004 to 2013 indicated that susceptibility remained high, although decreases in susceptibility over time had been noted, for example against Enterobacter spp in Latin America [43].

**Pharmacokinetics/pharmacodynamics of tetracycline-class drugs**

Pharmacokinetic (PK)/PD characteristics, and thus drug dosage and dosing frequency, and available formulations of the tetracycline-class agents, vary: overall, tetracycline-class drugs have a longer half-life than older drugs, which supports once- or twice-daily administration (Table 5). Eravacycline and tigecycline, despite their prolonged half-lives, are dosed twice daily to improve tolerability related to concentration-dependent gastrointestinal adverse events (AEs) [44–46]. Dose adjustment is not required for the newer generation of tetracycline agents in patients with renal impairment. Doses need to be adjusted only for eravacycline and tigecycline in patients with severe hepatic impairment [8,10,12].

**Pharmacokinetics**

Absorption of tetracycline-class drugs is variable and ranges from approximately 25–60% for first-generation drugs to (near) complete absorption for later generations [47]. The absorption of all tetracycline-class drugs is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations [47]. Data on first- and
second-generation drugs are limited (owing to their development and approval before current regulatory standards were in place), but third-generation tetracycline-class antibiotics are known to have a high volume of tissue distribution including in pulmonary tissues [47,48]. Omadacycline, eravacycline, and tigecycline concentrations in unbound plasma, alveolar macrophages, and epithelial lining fluid are high, with a greater magnitude of omadacycline concentrations than those for the other two drugs (Figure 3). Tetracycline-class antibiotics are all metabolised, with the exception of tigecycline (Table 5) [47]. Excretion varies across the tetracycline class, but most of the drugs have a combination of majority biliary/fecal and some renal excretion [47].

**Pharmacodynamics**

The bacterial killing effect of second- and third-generation tetracycline agents has been evaluated in various in vitro and in vivo studies. Doxycycline demonstrates time-dependent killing at 2–4 times the MIC (i.e. low serum concentrations) but dose-dependent killing at higher concentrations (8–16 times the MIC) [49]. Post-antibiotic effect (PAE), the period after removal of the antibiotic after which no further bacterial growth occurs, is similar to doxycycline against both gram-negative and gram-positive organisms and is concentration dependent [49]. PAE for omadacycline varies with the pathogen tested, with similar PAE for tigecycline and eravacycline against *S. aureus*, *S. pneumoniae*, and *E. coli* [50,51].

As tetracycline-class drugs have substantial post-antibiotic effects, the area under the free concentration-time curve (fAUC) to MIC ratio is an important predictor of in vivo activity [46,47]. In vitro and in vivo studies of doxycycline showed fAUC/MICs of 24 and 25 to be associated with net stasis against *S. pneumoniae* and *S. aureus*, respectively [46,52]. For eravacycline, fAUC/MICs of 28.0 and 32.6 have been associated with net stasis and 1-log-kill endpoints, respectively, against *E. coli* in murine thigh infection models [46]. In PD studies of omadacycline, mean fAUC/MICs of 25.7 and 23.0 were required for stasis against *S. pneumoniae* and *E. coli*, respectively [53]. Data from neutropenic murine thigh and lung studies indicate the median fAUC/MICs required to achieve stasis for *S. aureus* and 1-log10 reduction for *S. pneumoniae* are 21.9 and 17.4, respectively [54,55]. For tigecycline, the mean effective exposure index at 80% for fAUC/MIC was 5.4 μg/mL (range, 2.8–13 μg/mL) against *S. aureus* in a murine thigh model [56].

**Clinical data on third-generation tetracycline-class antibiotics**

Third-generation tetracycline-class agents are approved for multiple therapeutic indications,
including skin and skin structure infections, CABP, and complicated intra-abdominal infection (cIAI) (Table 4). Approval for these indications was based on efficacy and safety data from phase 3 studies using standard-of-care oxazolidinones or glycopeptides, fluoroquinolones, or carbapenems as respective comparators [10,12,57]. These studies were all designed to align with then-current FDA guidance, which leads to some of the differences in endpoints as reported below.

Efficacy data

Community-acquired bacterial pneumonia

Omadacynle and tigecycline are approved for the treatment of adults with CABP. In the phase 3 OPTIC study, omadacynle was non-inferior to moxifloxacin in the treatment of hospitalised adults with CABP, based on the primary outcome of early clinical response (ECR), defined as survival with the improvement of at least two of four symptoms (cough, sputum production, pleuritic chest pain, and dyspnea) and no worsening of symptoms at 72–120 h, without receipt of rescue antibacterial therapy [58]. Similar findings were observed at post-treatment evaluation (PTE; 5–10 days after last dose of the study drug). Tigecycline also demonstrated non-inferiority to levo-floxacin in adults hospitalised for CABP based on clinical cure (all signs and symptoms of pneumonia improved or resolved, with no worsening of symptoms or new signs, and no requirement for further antibiotic therapy) at 10–21 days post therapy [59–62].

Skin and skin structure infections

Omadacynle and tigecycline are also indicated for the treatment of skin and skin structure infections; omadacynle is FDA approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), whereas tigecycline is approved for the treatment of complicated skin and skin structure infections (cSSSIs). ABSSSI is considered a more specific categorisation and is defined as a bacterial infection of the skin with a lesion size area of ≥75 cm², whereas cSSSIs involve abnormal skin, wounds, or infections in immunocompromised individuals or infections requiring surgery [62]. In the phase 3 OASIS-1 and OASIS-2 studies in adult patients with ABSSSIs, IV-to-oral or oral-only omadacynle was non-inferior to linezolid at ECR (48–72 h after the first dose), based on a > 20% reduction in lesion size, with similar rates of clinical success observed at PTE [63,64]. Tigecycline achieved non-inferiority to vancomycin and aztreonam at the test-of-cure visit (12–92 days after the last dose of the study drug) based on the resolution of signs and symptoms such that no further antibiotic therapy was required [65,66].

Complicated intra-abdominal infections

Tigecycline and eravacycline are approved by the FDA for the treatment of complicated IAIs. In the phase 3 IGNITE1 and IGNITE4 studies, eravacycline demonstrated non-inferiority to ertapenem and meropenem, respectively, in patients with cIAI based on clinical efficacy 25–31 days after the first dose of the study drug [67,68]. Clinical efficacy was defined as complete resolution or significant improvement of signs or symptoms of the index infection such that no additional antibacterial therapy, surgical, or radiological intervention was required. Similarly, tigecycline demonstrated non-inferiority to imipenem–cilastatin for the treatment of cIAI, based on clinical cure 12–42 days after the first dose of the study drug [69,70]. In these studies, the cure was defined as resolution of the IAI process following the course of study drug and initial intervention.

Safety, tolerability, and drug interactions

Tetracycline class effects

All tetracycline-class drugs, including the third-generation agents, come with warnings and precautions including tooth discoloration and enamel hypoplasia during tooth development (last half of pregnancy up until 8 years of age), and inhibition of bone growth (second trimester of pregnancy until 8 years of age). Tigecycline also has a boxed warning for increased mortality risk and should be reserved for situations when alternative treatments are not suitable [10]. Other tetracycline-class AEs include photosensitivity, pseudotumor cerebri, and anti-anabolic action. As seen with other drug classes, while these AEs are attributed to the tetracycline class as a whole, the magnitude of the effect varies between specific drugs within the class (e.g. photosensitivity [71]). Tetracycline-class drugs have been shown to depress plasma prothrombin activity; patients taking anticoagulants may therefore need to be monitored or have their oral anticoagulant dosage adjusted while taking tetracycline-class drugs [9,10,12]. There is impaired absorption of oral tetracycline-class drugs by antacids containing aluminium, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations [9].

C. difficile infection

The potential for C. difficile-associated diarrhea and the associated label warning is common to all
antibiotics, although there is evidence of lower rates of C. difficile infection (CDI) with the tetracycline class than with other classes of antibiotics, such as fluoroquinolones and third-generation cephalosporins [72–75]. Tigecycline has been used in select cases, usually for severe disease, as a successful adjunctive treatment for CDI [76]. Across the phase 3 studies of omadacycline, no cases of CDI were observed in the omadacycline treatment groups [77]. A retrospective study of 50 patients receiving eravacycline as an inpatient or outpatient parenteral antibiotic therapy reported only one case of post-treatment CDI, where 40% of these patients had experienced CDI in the 12 months before receiving eravacycline [78]. While the mechanism of decreased risk of CDI with tetracycline-class drugs remains unclear, high drug concentrations in the bowel, less disruption to the gut microbiota than observed with other antibiotics, and in vitro and in vivo activity against C. difficile may all play a role [75,79,80].

**Tigecycline**

Pooled data across various studies show that nausea and vomiting were the most frequently reported AEs (Table 6). These gastrointestinal AEs are $C_{\text{max}}$ related and thus dose-limiting; in general, the maximum single dose is 100 mg IV [44]. However, higher doses have been used in an attempt to maximise efficacy, which resulted in increased AEs and discontinuation [81], leading to attempts at reduced dosing of 25 mg once or twice daily in some long-term utilisation studies to minimise gastrointestinal side effects (e.g. [82]). Across clinical trials, 7% of 2514 patients discontinued tigecycline due to AEs, compared with 6% of those taking the comparator drugs [10].

A meta-analysis of phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in tetracycline-treated patients compared with controls, with a risk difference of 0.6% (95% CI 0.1, 1.2). The cause of this increase has not been established, and the increase was also seen when limited to approved indications. The greatest differences in mortality versus controls were observed in patients with ventilator-assisted pneumonia [10], which is not an FDA-approved indication for tigecycline.

**Eravacycline**

Nausea and vomiting are also frequently reported AEs for eravacycline (Table 6), with a trend towards increasing incidence of nausea and vomiting with increasing eravacycline $C_{\text{max}}$ [46]. Rates of nausea were higher with twice- versus once-daily administration (11% vs 2%), but rates of vomiting were lower (2% vs 6%) [83]. Local infusion-site reactions, most of which were mild, were also more frequent with eravacycline than the comparator drug in phase 3 studies [67,68]. Across clinical trials, 2% of 520 patients receiving eravacycline discontinued due to AEs, compared with 2% of patients who received the comparator [12]. Mortality rates were similar to those observed for the comparator drugs [67,68].

**Omadacycline**

Nausea and vomiting were the most frequently observed AEs in the omadacycline group (15% and 8%, respectively) (Table 6). This was largely driven by higher rates of nausea and vomiting reported during the high dose oral-only (450 mg) loading period in the first 2 days of the OASIS-2 study [63,77], with rates similar to the comparators in the IV-to-oral OPTIC (omadacycline, 2.4% and 2.6%; moxifloxacin, 5.4% and 1.5% for nausea and vomiting, respectively) and OASIS-1 trials (omadacycline, 12.4% and 5.3%; linezolid, 9.9% and 5.0% for nausea and vomiting, respectively) [58]. Discontinuation rates were 5.5% of 382 patients with CABP (7.0% for comparator) and 1.7% of 691 patients with ABSSSI (1.5% for comparator) [58,64]. An imbalance of mortality was observed for omadacycline (2%) versus moxifloxacin (1%) in the CABP OPTIC study, although the cause of this imbalance has not been established.

**Special patient populations**

Use of tetracycline-class drugs in pregnancy and for children under 8 years of age should be avoided, unless the benefit outweighs the risk, due to the risk of permanent tooth discolouration, enamel hypoplasia, and inhibition of bone growth. No dosage adjustments are needed for any of the third-generation tetracyclines in patients with renal impairment or mild-to-moderate hepatic impairment. However, dosage adjustments are required for eravacycline and tigecycline in patients with severe hepatic impairment (Child–Pugh Class C). Patient weight can impact PK and outcomes for some antibiotics, which may therefore require patient-specific dosing. Studies in most third-generation tetracycline-class antibiotics indicate that no adjustments are needed based on body weight [84], although dosing of eravacycline is based on 1 mg/kg body weight [12]. Efficacy of omadacycline and eravacycline is consistent across body mass index (BMI) groupings [57,85,86], and the PK of tigecycline is similar in patients with class III obesity (BMI $\geq$40 kg/m$^2$) or healthy weight [87]. Additionally, safety data
indicate tolerance of higher-dose eravacycline in patients with increased BMI [85].

Drug-drug interactions (DDIs) leading to adverse drug events are a common cause of emergency department visit and/or hospitalisation [88,89]. Patients, particularly at risk of these DDIs, are older patients who are on many long-standing medications, immunocompromised patients, and others with multiple medical problems [90]. Based on their PK/PD characteristics and ability to be used as monotherapy, newer tetracycline-class agents can be used to minimise the risk of severe drug-drug interactions in these high-risk patients.

Patients with labeled drug-drug penicillin allergy in the past have had multiple negative outcomes associated with the use of alternative antimicrobial agents including the risk of antimicrobial treatment failure, antimicrobial resistance, adverse drug reactions from the use of a broader-spectrum or alternative antibiotic, increased risk of CDI, and increased healthcare costs [91,92]. In these patients, a newer generation of tetracycline-class agents could provide a therapeutic option that is not only efficacious but also mitigates the risk of various negative sequelae.

The risk of recurrent CDI is higher in patients aged ≥65 years, or who have compromised immunity, prior

Table 6. Most frequently (≥2%) occurring adverse events from pooled phase 3 clinical studies of third-generation tetracycline-class drugs [10,12,77].

| Indication       | Adverse event               | Tetracycline-class agent | Comparator |
|------------------|-----------------------------|--------------------------|------------|
| **Omadacycline** |                             |                          |            |
| ABSSSI, CABP     | N = 1073                    | N = 1077<sup>a</sup>     |            |
|                  | Nausea                      | 15%                      | 8%         |
|                  | Vomiting                    | 8%                       | 3%         |
|                  | ALT increased               | 4%                       | 4%         |
|                  | AST increased               | 3%                       | 4%         |
|                  | Headache                    | 3%                       | 2%         |
|                  | Infusion-site extravasation | 3%                       | 2%         |
|                  | Wound infection             | 3%                       | 2%         |
|                  | Cellulitis                  | 3%                       | 2%         |
|                  | Diarrhoea                   | 2%                       | 5%         |
|                  | Subcutaneous abscess        | 2%                       | 3%         |
|                  | Hypertension                | 2%                       | 1%         |
| **Tigecycline**  |                             |                          |            |
| CABP, cSSSI, cIAI| N = 2514                    | N = 2307<sup>b</sup>     |            |
|                  | Nausea                      | 26%                      | 13%        |
|                  | Vomiting                    | 18%                      | 9%         |
|                  | Diarrhoea                   | 12%                      | 11%        |
|                  | Infection                   | 7%                       | 5%         |
|                  | Abdominal pain              | 6%                       | 4%         |
|                  | Headache                    | 6%                       | 7%         |
|                  | SGPT increased              | 5%                       | 5%         |
|                  | Anemia                      | 5%                       | 6%         |
|                  | Hypoproteinemia             | 5%                       | 3%         |
|                  | SGOT increased              | 4%                       | 5%         |
|                  | Phlebitis                   | 3%                       | 4%         |
|                  | Rash                        | 3%                       | 4%         |
|                  | Alkaline phosphatase increased| 3%                      | 3%         |
|                  | Dizziness                   | 3%                       | 3%         |
|                  | Asthenia                    | 3%                       | 2%         |
|                  | Amylase increased           | 3%                       | 2%         |
|                  | Abnormal healing            | 3%                       | 2%         |
|                  | BUN increased               | 3%                       | 1%         |
|                  | Abscess                     | 2%                       | 2%         |
|                  | Dyspepsia                   | 2%                       | 2%         |
|                  | Pneumonia                   | 2%                       | 2%         |
|                  | Bilirubinemia               | 2%                       | 1%         |
|                  | Hyponatremia                | 2%                       | 1%         |
| **Eravacycline** |                             |                          |            |
| cIAI             | N = 520                     | N = 517<sup>c</sup>      |            |
|                  | Infusion-site reactions     | 8%                       | 2%         |
|                  | Nausea                      | 7%                       | 0.6%       |
|                  | Vomiting                    | 4%                       | 3%         |
|                  | Diarrhoea                   | 2%                       | 2%         |

<sup>a</sup>Comparators: linezolid, moxifloxacin.
<sup>b</sup>Comparators: vancomycin–aztreonam, imipenem–cilastatin, levofloxacin, linezolid.
<sup>c</sup>Comparators: ertapenem, meropenem.
ABSSSI: acute bacterial skin and skin structure infection; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CABP: community-acquired bacterial pneumonia; cIAI: complicated intra-abdominal infection; cSSSI: complication skin and skin structure infection; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase.
severe CDI, or ribotype 027/078/244 infections [93]. If these patients require ongoing or repeat antibiotic therapy immediately after the initial episode of CDI, then antibiotics with known increased risk of CDI (clindamycin, fluoroquinolones, β-lactam agents) could be avoided.

**Re-engaging with tetracycline-class drugs – where could patients benefit?**

Antimicrobial stewardship involves using the right antibiotic agent, at the right time, for the right patient. While the clinical utility of first- and second-generation tetracycline-class drugs has been decreasing, third-generation drugs overcome the most common acquired tetracycline resistance mechanisms and therefore may play an important role in antimicrobial stewardship and in reducing “collateral damage” of antibiotic therapies. The increases in extended-spectrum β-lactamase (ESBL)-producing bacteria have limited the use of β-lactams in both hospital and outpatient settings [94,95]. The broad-spectrum activity of the third-generation tetracycline-class agents, combined with their activity being unaffected by common resistance genes, including β-lactamases, makes them suitable for treating a wide range of infections including those caused by drug-resistant strains, such as MRSA, vancomycin-resistant enterococci, tetracycline-resistant S. pneumoniae, and anaerobic pathogens [35,96–101]. Additionally, these drugs can be used as a monotherapy to treat polymicrobial infections, such as IAIs and skin structure infections, thereby minimising the impact on global antimicrobial resistance. The emerging threat of the tet(X) which causes resistance to all tetracyclines but not to other antibiotic classes, warrants continued monitoring of tetracycline resistance, further restriction of tetracyclines (and other antibiotics) in farm animals, and robust antimicrobial stewardship to promote their optimal use including considerations to reduce selective pressure potential by deprioritizing the use of tetracyclines for pathogens that may harbour tet(X). In addition to the currently approved indications for the third-generation tetracycline-class drugs, clinical trials are ongoing in diabetes-related infections (NCT04144374), cystic fibrosis (NCT04460586), pulmonary Mycobacterium abscessus complex (NCT04922554) and multidrug-resistant blood-stream infections (NCT04489459, NCT04876430).

The reduced risk of CDI compared with other antibiotic classes such as β-lactams and fluoroquinolones suggest that third-generation tetracycline-class drugs may present alternative antibiotic treatment options for patients with an increased risk of primary or recurrent CDI.

As third-generation tetracycline-class drugs do not require dose adjustments for end-stage renal impairment or mild-to-moderate hepatic impairment and have a limited number of DDIs, they provide a suitable therapy option for patients who otherwise could experience reduced efficacy with other antimicrobial agents, and for older adults who are often taking multiple chronic medications.

Finally, the mode of delivery and frequency of administration may provide benefits to patients over previous therapies. For example, the availability of doxycycline, minocycline, and omadacycline as IV-to-oral therapies could potentially reduce inpatient treatment times, and oral-only options allow outpatient treatment of patients with appropriate indications who may otherwise have required IV therapy. Similarly, oral medications including antibiotics that require infrequent dosing can also improve treatment adherence and patient compliance [102].

In summary, in an era of multidrug antibiotic resistance, additional treatment options are needed to address infections in complex patient populations. The latest generation of tetracycline-class antibiotics overcome the most common mechanisms of tetracycline resistance that limit the use of prior tetracyclines and are well suited to treat various infectious syndromes including skin-soft tissue infections, community acquired pneumonia and intra-abdominal infections. While all antibiotics are subject to the development of resistance, judicious use of tetracyclines not only provides another class of antibiotic activity but also helps by not promoting resistance to other commonly used antibiotic classes (e.g. β-lactams, fluoroquinolones). Therefore, the third-generation tetracycline class has the potential to play a key role in the treatment of a broad range of bacterial infections to provide a safe and effective treatment option for patients and to support antibiotic stewardship initiatives.

**Acknowledgements**

The medical writing support was provided by Jenny Engelmoer, Ph.D., of Innovative Strategic Communications, LLC, funded by Paratek Pharmaceuticals, Inc.

**Disclosure statement**

KLP has received research grants from Merck and Pfizer and served as a consultant for Paratek Pharmaceuticals, Inc. and Ferring Pharmaceuticals, Inc. AD has received honoraria from
Funding
This work was supported by the Paratek Pharmaceuticals, Inc.

Data availability statement
Data sharing is not applicable to this article as no new data were created or analysed in this study.

References
[1] Centers for Disease Control and Prevention. Antibiotic resistant threats in the United States; 2019. https://www.cdc.gov/drugresistance/biggest-threats.html.
[2] Nelson RE, Hatfield KM, Wolford H, et al. National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin Infect Dis. 2021;72(Suppl 1):S17–S26.
[3] The 10 x ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1686–1083.
[4] Talbot GH, Jezek A, Murray BE, et al. The Infectious Diseases Society of America’s 10 x ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): is 20 x ’20 a possibility? Clin Infect Dis. 2019;69(1):1–11.
[5] Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260.
[6] Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother. 2016;60(8):4433–4441.
[7] Eliopoulos GM, Eliopoulos GM, Roberts MC. Tetracycline therapy: update. Clin Infect Dis. 2003;36(4):462–467.
[8] Pharma AA. Tetracycline (tetracycline hydrochloride) prescribing information. 2010. https://www.aapharma.ca/downloads/en/PIL/Tetracycline_PI.pdf.
[9] Paratek Pharmaceuticals. Nuyzra(R) (omadacycline) prescribing information. 2020. https://www.nuyzra.com/nuyzra-pi.pdf.
[10] Pfizer. TYGACIL® (tigecycline) prescribing information. 2005. https://www.pfizermedicalinformation.com/en-us/tygacil.
[11] Apotex Inc. Doxycycline hyclate prescribing information. 2016. https://pdf.hres.ca/dpd_pm/00037247.PDF.
[12] Tetraphase Pharmaceuticals. XERAVA (eravacycline) prescribing information. 2020. https://www.tphase.com/products/xerava/.
[13] Valeant Pharmaceuticals. MINOCIN® (minocycline hydrochloride) prescribing information. 2019. https://www.fda.gov/media/121327/download.
[14] Dowling HF, Lepper MH, Jackson GG. Observations on the epidemiological spread of antibiotic-resistant staphylococci, with measurements of the changes in sensitivity to penicillin and aureomycin. Am J Public Health Nations Health. 1953;43(7):860–868.
[15] Lowbury EJ, Cason JS. Aureomycin and erythromycin therapy for str. pyogenes in burns. Br Med J. 1954;2(4893):914–915.
[16] Percival A. Increased incidence of tetracycline-resistant pneumococci in Liverpool in 1968. Lancet. 1969;1(7603):998–1000.
[17] Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003;51(90001):13–20.
[18] Markley JL, Wencewicz TA. Tetracycline-inactivating enzymes. Front Microbiol. 2018;9:1058.
[19] Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med. 2016;6(4):a025387.
[20] Fang LX, Chen C, Cui C-Y, et al. Emerging high-level tigecycline resistance: novel tetracycline destrucatases spread via the mobile tet(X). BioEssays. 2020;42(8):2000014.
[21] Kadavy DR, Hornby JM, Haverkost T, et al. Natural antibiotic resistance of bacteria isolated from larvae of the oil fly, Helaeomyia petrolei. Appl Environ Microbiol. 2000;66(11):4615–4619.
[22] Stock I. Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. J Chemother. 2003;15(1):12–26.
[23] Li XZ, Livernmore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother. 1994;38(8):1732–1741.
[24] Diekema DJ, Pfaller MA, Shortridge D, et al. Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6(Suppl 1):s47–s53.
[25] Gupta V, Yu KC, Schranz J, et al. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States. Open Forum Infect Dis. 2021;8(7):ofab063.
[26] Huband MD, Pfaller MA, Streit JM, et al. Activity of omadacycline against 7,000 bacterial isolates from the United States in the SENTRY Antimicrobial Surveillance Program (2020). World Microbe Forum 2021. June 20–24.
[27] Jones RN, Stilwell MG, Wilson ML, et al. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing gram-positive pathogens. Diagn Microbiol Infect Dis. 2013;76(1):69–72.
[28] Jones RN, Wilson ML, Weinstein MP, et al. Contemporary potencies of minocycline and tetracycline HCL tested against gram-positive pathogens: SENTRY program results using CLSI and EUCAST.
breakpoint criteria. Diagn Microbiol Infect Dis. 2013;75(4):402–405.

[29] Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559–575.

[30] Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycyclcline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43(4):738–744.

[31] Schwartz BS, Graber CJ, Diep BA, et al. Doxycycline, not minocycline, induces its own resistance in multi-drug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis. 2009;48(10):1483–1484.

[32] Mendes RE, Huband MD, Streit JM, et al. Omadacycline invito activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. Diagn Microbiol Infect Dis. 2020;97(3):115054.

[33] Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10(2):165.

[34] Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127–1135.

[35] Sutcliffe JA, O’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluoro cycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548–5558.

[36] Lijfrok V, Morgan S, Hwang S, et al. 1613. Global 2018 surveillance of eravacycline against gram-negative pathogens, including multi-drug resistant isolates. Open Forum Infect Dis. 2020;7(Supplement_1):S800–S.

[37] Morgan S, Hwang S, Efmova E, et al. 915. Global 2018 surveillance of eravacycline against gram-positive pathogens, including resistant isolates. Open Forum Infect Dis. 2020;7(Supplement_1):S549–55.

[38] Linkevicius M, Sandegren L, Andersson DI. Potential of tetracycline resistance proteins to evolve tigecycline resistance. Antimicrob Agents Chemother. 2016;60(2):789–796.

[39] Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents. 2013;41(2):110–116.

[40] Wen Z, Shang Y, Xu G, et al. Mechanism of eravacycline resistance in clinical Enterococcus faecalis isolates from China. Front Microbiol. 2020;11(916):916.

[41] He T, Wang R, Liu D, et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019;4(9):1450–1456.

[42] Sun J, Chen C, Cui CY, et al. Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat Microbiol. 2019;4(9):1457–1464.

[43] Hoban DJ, Reinert RR, Bouchillon SK, et al. Global in vitro activity of tigecycline and comparator agents: Tigecycline evaluation and surveillance trial 2004–2013. Ann Clin Microbiol Antimicrob. 2015;14:27.

[44] Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220–229.

[45] Center for Drug Evaluation and Research. Eravacycline multi-discipline review; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf.

[46] Zhao M, Lepak AJ, Marchillo K, et al. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(7):e00250–17.

[47] Agwu KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycycyclines. J Antimicrob Chemother. 2006;58(2):256–265.

[48] Burgos RM, Rodvold KA. Omadacycline: a novel aminomethylcycline. Infect Drug Resist. 2019;12:1895–1915.

[49] Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect. 2000;6(5):270–273.

[50] Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6209–6419.

[51] Center for Drug Evaluation and Research. Xerava (eravacycline): NDA multidisciplinary review and evaluation 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf.

[52] LaPlante KL, Leonard SN, Andes DR, et al. Activities of clindamycin, dapto mycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother. 2008;52(6):2156–2162.

[53] Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69(Suppl 1):S16–S22.

[54] Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63(7):e00634–19.

[55] Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):e02368–16.

[56] Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother. 2009;53(3):1165–1169.

[57] Pai MP, Wilcox MH, Chitra S, et al. Safety and efficacy of omadacycline by BMI categories and
diabetes history in two phase III randomized studies of patients with acute bacterial skin and skin structure infections. J Antimicrob Chemother. 2021;76(5):1315–1322.

[58] Stets R, Popescu M, Gonong JR, et al. Omadaclyline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–527.

[59] Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63(1):52–61.

[60] Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009;9:44.

[61] US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment; 2014. http://www.fda.gov/media/75149/download.

[62] US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Acute bacterial skin and skin structure infections: developing drugs for treatment; 2013. http://www.fda.gov/media/71052/download.

[63] O’Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadaclyline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080–1090.

[64] O’Riordan W, Green S, Overcash JS, et al. Omadaclyline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380(6):528–538.

[65] Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin–aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658–4666.

[66] Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251–261.

[67] Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224–232.

[68] Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2019;69(6):921–929.

[69] Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg. 2005;3(1):35–47.

[70] Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem–cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005;5:88.

[71] Bjellerup M, Ljunggren B. Photohemolytic potency of tetracyclines. J Invest Dermatol. 1985;84(4):262–264.

[72] Brown KA, Khanafier N, Daneman N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326–2332.

[73] Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881–891.

[74] Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–1961.

[75] Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(4):514–522.

[76] Kechagias KS, Chorepsima S, Triarides NA, et al. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis. 2020;39(6):1053–1058.

[77] Opal S, File TM Jr, van der Poll T, et al. An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis. 2019;69(Suppl 1):S40–S57.

[78] Van Hise N, Petrak RM, Skorodin NC, et al. A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline. Infect Dis Ther. 2020;9(4):1017–1028.

[79] Moura IB, Buckley AM, Ewin D, et al. Omadacycline gut microbiome exposure does not induce clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human Colon. Antimicrob Agents Chemother. 2019;63(2):e01581–18.

[80] Garey KW, Rose W, Gunter K, et al. Omadacycline and Clostridiodes difficile: a systematic review of preclinical and clinical evidence. Ann Med.

[81] Lauf L, Ozsvár Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014;78(4):469–480.

[82] Wallace RJ Jr, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69(7):1945–1953.
versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847–1854.

[84] Pai MP. Antimicrobial dosing in specific populations and novel clinical methodologies: obesity. Clin Pharmacol Ther. 2021;109(4):942–951.

[85] Asempa TE, Izmailyan S, Lawrence K, et al. Efficacy and safety of eravacycline in obese patients: a post hoc analysis of pooled data from the IGNITE1 and IGNITE4 clinical trials. Open Forum Infect Dis. 2020; 7(12):ofaa548.

[86] Pai MP, Wilcox M, Chitra S, et al. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: sub-analysis from a randomized controlled trial. Respir Med. 2021;184:106442.

[87] Pai MP. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother. 2014;69(1):190–199.

[88] Swart F, Bianchi G, Lenzi J, et al. Risk of hospitalization from drug-drug interactions in the elderly: real-world evidence in a large administrative database. Aging. 2020;12(19):19711–19739.

[89] Dookeeram D, Bidaisee S, Paul JF, et al. Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean. Int J Clin Pharm. 2017;39(5):1119–1127.

[90] Bjerrum L, Gonzalez Lopez-Valcarcel B, Petersen G. Risk factors for potential drug interactions in general practice. Eur J Gen Pract. 2008;14(1):23–29.

[91] MacFadden DR, LaDelfa A, Leen J, et al. Impact of reported beta-lactam allergy on inpatient outcomes: a multicenter prospective cohort study. Clin Infect Dis. 2016;63(7):904–910.

[92] Assimon MM, Pun PH, Wang L, et al. Analysis of respiratory fluoroquinolones and the risk of sudden cardiac death among patients receiving hemodialysis. JAMA Cardiol. 2021;7(1):75.

[93] Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18:21–27.

[94] Thaden JT, Fowler VG, Sexton DJ, et al. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol. 2016;37(1):49–54.

[95] Coque T, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47):19044.

[96] Stone TJ, Kilic A, Williamson J, et al. 1267. Comparative activity of omadacycline against extended-spectrum beta-lactamase positive and negative Escherichia coli and Klebsiella pneumoniae strains recovered from urine specimens. Open Forum Infect Dis. 2020;7(Supplement_1):S650–S650.

[97] Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis. 2013;76(2):217–221.

[98] Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588.

[99] Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80(3):285–313.

[100] Xiao M, Huang J-J, Zhang G, et al. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol. 2020;20(1):350.

[101] Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69(Suppl 1):S56–S15.

[102] Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419–434.

[103] Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488–19.

[104] Morrissey I, Hawser S, Lob SH, et al. In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64(3):e01715–19.

[105] Grossman TH, Murphy TM, Slee AM, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015;59(5):2567–2571.

[106] Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998;317:657–660.